Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Am J Clin Pathol. 2010 Dec;134(6):880-5. doi: 10.1309/AJCPK6QHNNOEMJIM.
HER2 overexpression and amplification have been studied as a therapeutic and prognostic target in a number of human cancers, including esophageal, gastric, and colorectal adenocarcinomas. However, HER2 status has not been well investigated in primary small intestinal adenocarcinoma, probably because of its rarity. In this study, we conducted immunohistochemical analysis and fluorescence in situ hybridization (FISH) for HER2 on 49 primary nonampullar small intestinal adenocarcinomas. The results showed a complete lack of HER2 protein expression in 47 cases (96%) by immunohistochemical analysis. Only 2 cases (4%) showed a 1+ staining pattern. No tumors exhibited 2+ or 3+ HER2 immunoreactivity. By FISH, none of the tumors, including those with 1+ HER2 immunoreactivity, exhibited HER2 gene amplification. These observations demonstrate that HER2 protein overexpression and gene amplification are infrequent events, if they occur at all, in small intestinal adenocarcinoma. Thus, routine immunohistochemical and/or FISH testing for HER2 for potential targeted anti-HER2 therapy may not be beneficial for patients with primary small intestinal adenocarcinoma.
HER2 过表达和扩增已被研究作为多种人类癌症（包括食管、胃和结直肠腺癌）的治疗和预后靶点。然而，HER2 状态在原发性小肠腺癌中尚未得到充分研究，可能是因为其罕见。在这项研究中，我们对 49 例原发性非壶腹小肠腺癌进行了 HER2 的免疫组织化学分析和荧光原位杂交（FISH）检测。结果显示，免疫组织化学分析显示 47 例（96%）完全缺乏 HER2 蛋白表达。只有 2 例（4%）显示 1+染色模式。没有肿瘤显示 2+或 3+HER2 免疫反应性。通过 FISH，包括那些具有 1+HER2 免疫反应性的肿瘤在内，均未显示 HER2 基因扩增。这些观察结果表明，HER2 蛋白过表达和基因扩增是罕见事件，如果发生的话，在小肠腺癌中也是如此。因此，对于原发性小肠腺癌患者，常规进行 HER2 的免疫组化和/或 FISH 检测以进行潜在的靶向抗 HER2 治疗可能无益。
